Arizona State Retirement System increased its stake in shares of POINT Biopharma Global Inc. (NASDAQ:PNT – Get Rating) by 59.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,613 shares of the company’s stock after acquiring an additional 6,592 shares during the quarter. Arizona State Retirement System’s holdings in POINT Biopharma Global were worth $128,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. BlackRock Inc. boosted its holdings in shares of POINT Biopharma Global by 0.3% in the third quarter. BlackRock Inc. now owns 6,152,597 shares of the company’s stock valued at $47,560,000 after acquiring an additional 16,099 shares in the last quarter. BVF Inc. IL raised its stake in POINT Biopharma Global by 66.0% during the third quarter. BVF Inc. IL now owns 5,590,048 shares of the company’s stock worth $43,211,000 after purchasing an additional 2,222,222 shares during the period. PFM Health Sciences LP purchased a new position in POINT Biopharma Global during the third quarter worth approximately $34,903,000. Vanguard Group Inc. increased its position in shares of POINT Biopharma Global by 12.4% in the third quarter. Vanguard Group Inc. now owns 3,875,322 shares of the company’s stock worth $29,957,000 after acquiring an additional 426,617 shares in the last quarter. Finally, Point72 Asset Management L.P. increased its position in shares of POINT Biopharma Global by 89.0% in the third quarter. Point72 Asset Management L.P. now owns 3,692,620 shares of the company’s stock worth $28,544,000 after acquiring an additional 1,738,391 shares in the last quarter. 72.77% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Separately, Raymond James raised their price objective on shares of POINT Biopharma Global from $10.00 to $11.00 and gave the stock an “outperform” rating in a report on Tuesday, March 7th. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat, POINT Biopharma Global presently has a consensus rating of “Buy” and a consensus target price of $16.25.
POINT Biopharma Global Stock Performance
POINT Biopharma Global (NASDAQ:PNT – Get Rating) last released its earnings results on Monday, March 27th. The company reported $1.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $1.79. The business had revenue of $226.58 million for the quarter, compared to analyst estimates of $260.00 million. On average, analysts forecast that POINT Biopharma Global Inc. will post -0.76 EPS for the current year.
POINT Biopharma Global Company Profile
POINT Biopharma Global Inc, a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors.
- Get a free copy of the StockNews.com research report on POINT Biopharma Global (PNT)
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
- Best Buy’s Comeback Is Still At Play, Earnings Call For Patience
- e.l.f. Beauty Has Giant Quarter, Shares Hit New High
- If You Can Only Pick One Stock For The Rest Of 2023, Pick Nvidia
Want to see what other hedge funds are holding PNT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for POINT Biopharma Global Inc. (NASDAQ:PNT – Get Rating).
Receive News & Ratings for POINT Biopharma Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for POINT Biopharma Global and related companies with MarketBeat.com's FREE daily email newsletter.